HBV TREATMENT

摘要

This invention is directed to a RNA interference (RNAi) agent and the use of that RNAi agent to treat hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agents, or constructs for expressing them are utilised to inhibit expression of at least one Hepatitis B virus (HBV) gene, where the agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some forms of the invention, the agent has more than one effector sequence. Multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.

主权项

1. A DNA-directed RNA interference (ddRNAi) agent for inhibiting expression of one or more target sequences in one or more Hepatitis B virus (HBV) genes, the ddRNAi agent comprising:
a first effector sequence of at least 17 nucleotides in length; a second effector sequence of at least 17 nucleotides in length; a second effector complement sequence; and a first effector complement sequence;wherein each effector sequence is substantially complementary to the predicted transcript of a target sequence.